Small cell neuroendocrine cancers (SCNCs) are recalcitrant cancers arising from diverse
primary sites that lack effective treatments. Using chemical genetic screens, we identified …

Diffuse midline gliomas (DMGs) are universally lethal malignancies occurring chiefly during
childhood and involving midline structures of the central nervous system, including thalamus…

Drug repurposing is a rapid approach to identify therapeutics for the treatment of emerging
infectious diseases such as COVID-19. To address the urgent need for treatment options, we …

The COVID-19 pandemic, caused by SARS-CoV-2, is a pressing public health emergency
garnering a rapid response from scientists across the globe. Host cell invasion is initiated …

Combination of anti-cancer drugs is broadly seen as way to overcome the often-limited efficacy
of single agents. The design and testing of combinations are however very challenging. …

The National Center for Advancing Translational Sciences (NCATS) has developed an online
open science data portal for its COVID-19 drug repurposing campaign–named OpenData–…

In diffuse large B-cell lymphoma, we show that primary resistance to BTK inhibitors is due to
epigenetic rather than genetic changes that circumvent the BTK blockade. We also …

Targeted inhibitors to oncogenic kinases demonstrate encouraging clinical responses early
in the treatment course; however, most patients will relapse because of target-dependent …

Tyrosine kinase domain (TKD) mutations contribute to acquired resistance to FMS-like tyrosine
kinase 3 (FLT3) inhibitors used to treat FLT3-mutant acute myeloid leukemia (AML). We …

Despite relative success of therapy for Hodgkin’s lymphoma (HL), novel therapeutic agents
are needed for patients with refractory or relapsed disease. Recently, anti-PD1 …